Inhibitorkänsliga

Inhibitorkänsliga is a Swedish term used in pharmacology, biochemistry and related fields to describe molecules, enzymes, pathways, or cellular processes that are particularly susceptible to inhibition by a specific inhibitor. When something is inhibitorkänsligt, low concentrations of the inhibitor are typically sufficient to reduce activity, signaling, or function significantly. The term is often contrasted with inhibitorresistenta or inhibitorknäsliga, which describe systems that require higher concentrations or that maintain activity in the presence of the inhibitor.

Sensitivity is commonly quantified using standard pharmacological or enzymological metrics such as IC50 (the inhibitor concentration that reduces activity by 50%) or Ki (binding affinity). Experimental approaches include in vitro enzyme assays, receptor binding studies, and cell-based assays to assess how readily a given system responds to inhibition. Factors influencing inhibitorkänslighet include the inhibitor’s binding affinity, the accessibility of the target site, competing substrates, and the presence of compensatory pathways.

Inhibitorkänsliga phenomena are relevant across drug development, toxicology, and signaling research. For example, enzymes with high affinity for a drug or receptors with accessible active sites may show inhibitorkänslighet, guiding dose selection and therapeutic windows. Genetic variations, post-translational modifications, or environmental conditions can also alter sensitivity, shifting a system toward greater or lesser inhibitorkänslighet over time. Understanding this property helps distinguish true sensitivity from adaptive resistance and informs strategies for effective inhibition.